-
Global Cancer Monoclonal Antibody Collaboration and Licensing Deals Analysis Report 2023 with Directory of 569 Deals Signed Since 2016 - ResearchAndMarkets.com
15 Nov 2023 14:31 GMT
… each contract document on demand.
Cancer Monoclonal Antibody Collaboration and Licensing … company profiles
Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory … - Cancer monoclonal antibody deals by therapy area
Companies Mentioned
3SBio
Abpro …
-
3SBio Inc. (OTCMKTS:TRSBF) Short Interest Down 67.8% in August
14 Sep 2023 16:35 GMT
… is presently ∞ days.
3SBio Price Performance
TRSBF stock … Great Investing Ideas?
3SBio Inc, an investment … -positive metastatic breast cancer in combination with chemotherapy … cancer and tuberculosis.
Featured Stories
Receive News & Ratings for 3SBio …
-
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
25 Aug 2023 05:20 GMT
… Chinese leading biopharmaceutical company 3SBio (01530.HK) today … the Diagnosis and Treatment of Cancer Therapy Induced Thrombocytopenia (CTIT … patients." About 3SBio Inc. 3SBio is a leading … China. Please visit www.3sbio.com for additional information …
-
China Cancer Antibodies Market Trends & Clinical Trials Insight Report 2023: Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach - ResearchAndMarkets.com
05 Jun 2023 20:26 GMT
… developed for different solid cancers considering the patients … in patients with solid tumors.
China's … players.
Report Highlights:
China Cancer Antibodies (Monoclonal, Bispecific, Trispecific … Competitive Landscape
13.1 3SBio
13.2 AD Pharmaceuticals
…
-
3SBio Inc. (OTCMKTS:TRSBF) Sees Large Decline in Short Interest
14 May 2023 07:35 GMT
… $0.80.
About 3SBio
(Get Rating)
3SBio Inc, an investment … immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid … HER2-positive metastatic breast cancer in combination with chemotherapy. … ' ratings for 3SBio and related companies with …
-
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
22 Mar 2023 04:45 GMT
… the Diagnosis and Treatment of Cancer Therapy Induced Thrombocytopenia (CTIT) … medium and chromatography filling . 3SBio will focus on providing … geared up
In 2022, 3SBio continued to accelerate external … drugs."
About 3SBio Inc.
3SBio is a leading bio …
-
Oral Biologics & Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com
05 Oct 2022 19:29 GMT
… such as arthritis, asthma, and cancer is expected to propel the … Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors
2 …
Chiasma
Allena Pharmaceuticals
Gelgen
Ganlee
3sbio
Innovent
Retractable Technologies, Inc.
…
-
Biosimilars Market Expected To Reach A Value Of $42 Billion By 2026 Due To The Rise In Number Of Cancer Cases Across The Globe As Per The Business Research Company's Biosimilars Global Market Report 2022
22 Jun 2022 15:30 GMT
… International, Allergan plc, BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis … -CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell …
-
Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022: Disclosed Headlines, Upfronts, Milestones and Royalties by Stage of Development - ResearchAndMarkets.com
13 Jun 2022 09:58 GMT
… development and commercialization of cancer monoclonal antibody technologies and products … antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2015 … active Cancer monoclonal antibody dealmakers since 2015
Companies Mentioned
3SBio
Abpro …
-
Global Oral Biologics & Biosimilar Drugs Markets, 2016-2021, 2021-2026F, 2031F: Lymphocyte Modulators, Interleukin Inhibitors, & Tumor Necrosis Factor-Alpha Inhibitors - ResearchAndMarkets.com
17 May 2022 11:52 GMT
… , Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun … such as diabetes, arthritis, cancer. Biologics are drugs made from … modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors. …
About
© 1995-2025